NuCana's Former CFO Joins Aurion Biotech to Drive Vision Restoration Initiatives

Aurion Biotech Welcomes Financial Leader to Propel Vision Restoration Initiatives

Aurion Biotech, Inc. strengthens its leadership team with the appointment of Donald Munoz as the new chief financial officer (CFO). Munoz, who has over 30 years of experience in healthcare, holds a significant history in financial management and fundraising, notably during his tenure at NuCana plc. His previous role at NuCana saw him successfully overseeing critical financial operations and navigating the company through substantial fundraising rounds, including a $114 million initial public offering and an $80 million follow-on offering. This extensive background equips Munoz with the financial acumen needed to enhance Aurion's growth trajectory as the company focuses on innovative therapies for vision restoration.

As Aurion's CFO, Munoz expresses enthusiasm about the potential of the company’s lead product candidate, AURN001. This therapy targets corneal endothelial disease, a condition that can lead to blindness. Munoz's appointment comes on the heels of promising results from Aurion’s CLARA Phase 1/2 clinical trial, which demonstrated positive six-month top-line data. The company’s commitment to restoring vision is further emphasized by its recent achievements, including the launch of the first commercially available corneal endothelial cell therapy in Japan. With Munoz at the financial helm, Aurion aims to leverage its clinical successes to secure the necessary funding for advancing AURN001 and other innovative treatments.

Aurion Biotech's recognition as the best biotech startup at the Prix Galien awards in 2022 reflects its commitment to pioneering regenerative therapies. Munoz’s extensive background in healthcare investment banking, which encompasses over 100 financing and advisory transactions, positions him as a valuable asset. As Aurion embarks on its ambitious mission to provide life-changing therapies, Munoz's leadership will likely play a pivotal role in navigating the financial landscape to support the company’s innovative projects in vision restoration.

In addition to Munoz's appointment, Aurion's recent clinical successes bolster its standing in the biotech industry. The company’s focus on regenerative therapies not only aims to address corneal endothelial disease but also sets a precedent for future advancements in ophthalmic treatments. Aurion’s commitment to innovation continues to attract attention within the healthcare sector, and with seasoned professionals like Munoz on board, the company is poised for significant growth and success in the coming years.